- Title Pages
- Dedication
- Acknowledgments
- Introduction
-
Chapter One Historical Themes and Developments at FDA Over the Past Fifty Years - Introduction
-
Chapter Two A Global and Innovative Regulatory Environment for the U.S. FDA -
Chapter Three FDA and the Rise of the Empowered Patient -
Chapter Four After the FDA -
Chapter Five The Future of Prospective Medicine Under the Food and Drug Administration Amendments Act of 2007 - Introduction
-
Chapter Six Global Trends Toward Transparency in Participant-Level Clinical Trials Data -
Chapter Seven Conflicts of Interest in FDA Advisory Committees -
Chapter Eight The Crime of Being in Charge -
Chapter Nine Recalibrating Enforcement in the Biomedical Industry - Introduction
-
Chapter Ten Prospects for Regulation of Off-Label Drug Promotion in an Era of Expanding Commercial Speech Protection -
Chapter Eleven The FDCA as the Test for Truth of Promotional Claims -
Chapter Twelve Why FDA’s Ban on Off-Label Promotion Violates the First Amendment - Introduction
-
Chapter Thirteen Speed Versus Safety in Drug Development -
Chapter Fourteen Overcoming “Premarket Syndrome” -
Chapter Fifteen FDA’s Public Health Imperative - Introduction
-
Chapter Sixteen The Drug Efficacy Study and Its Manifold Legacies -
Chapter Seventeen Drug Safety Communication -
Chapter Eighteen Innovation Policy Failures in the Manufacturing of Drugs - Introduction
-
Chapter Nineteen From “Recycled Molecule” to Orphan Drug -
Chapter Twenty FDA, Negotiated Rulemaking, and Generics -
Chapter Twenty-One The “Follow-On” Challenge -
Chapter Twenty-Two FDA Regulation of Biosimilars - Introduction
-
Chapter Twenty-Three Analog Agency in a Digital World -
Chapter Twenty-Four Twenty-First-Century Technology with Twentieth-Century Baggage -
Chapter Twenty-Five Device-ive Maneuvers -
Chapter Twenty-Six A New Regulatory Function for E-Prescriptions -
Chapter Twenty-Seven Race and the FDA - Contributors
- Index
Prospects for Regulation of Off-Label Drug Promotion in an Era of Expanding Commercial Speech Protection
Prospects for Regulation of Off-Label Drug Promotion in an Era of Expanding Commercial Speech Protection
- Chapter:
- (p.184) Chapter Ten Prospects for Regulation of Off-Label Drug Promotion in an Era of Expanding Commercial Speech Protection
- Source:
- FDA in the Twenty-First Century
- Author(s):
Aaron S. Kesselheim
Michelle M. Mello
- Publisher:
- Columbia University Press
The FDA prevents prescription drug manufacturers from directly promoting their products for uses that the FDA has not validated (“off-label” uses), but in the recent case of United States v. Caronia, the United States Court of Appeals for the Second Circuit held that the First Amendment supports manufacturers’ freedom to advertise off-label uses. Since unfettered off-label promotion will lead to substantial public health risks, this chapter discusses how the government could make a stronger case that its current regulatory framework for off-label promotion satisfies the criteria of the First Amendment’s protection of commercial speech.
Keywords: Commercial speech, First Amendment, off label, FDA, pharmaceutical promotion, adverse effects
Columbia Scholarship Online requires a subscription or purchase to access the full text of books within the service. Public users can however freely search the site and view the abstracts and keywords for each book and chapter.
Please, subscribe or login to access full text content.
If you think you should have access to this title, please contact your librarian.
To troubleshoot, please check our FAQs, and if you can't find the answer there, please contact us .
- Title Pages
- Dedication
- Acknowledgments
- Introduction
-
Chapter One Historical Themes and Developments at FDA Over the Past Fifty Years - Introduction
-
Chapter Two A Global and Innovative Regulatory Environment for the U.S. FDA -
Chapter Three FDA and the Rise of the Empowered Patient -
Chapter Four After the FDA -
Chapter Five The Future of Prospective Medicine Under the Food and Drug Administration Amendments Act of 2007 - Introduction
-
Chapter Six Global Trends Toward Transparency in Participant-Level Clinical Trials Data -
Chapter Seven Conflicts of Interest in FDA Advisory Committees -
Chapter Eight The Crime of Being in Charge -
Chapter Nine Recalibrating Enforcement in the Biomedical Industry - Introduction
-
Chapter Ten Prospects for Regulation of Off-Label Drug Promotion in an Era of Expanding Commercial Speech Protection -
Chapter Eleven The FDCA as the Test for Truth of Promotional Claims -
Chapter Twelve Why FDA’s Ban on Off-Label Promotion Violates the First Amendment - Introduction
-
Chapter Thirteen Speed Versus Safety in Drug Development -
Chapter Fourteen Overcoming “Premarket Syndrome” -
Chapter Fifteen FDA’s Public Health Imperative - Introduction
-
Chapter Sixteen The Drug Efficacy Study and Its Manifold Legacies -
Chapter Seventeen Drug Safety Communication -
Chapter Eighteen Innovation Policy Failures in the Manufacturing of Drugs - Introduction
-
Chapter Nineteen From “Recycled Molecule” to Orphan Drug -
Chapter Twenty FDA, Negotiated Rulemaking, and Generics -
Chapter Twenty-One The “Follow-On” Challenge -
Chapter Twenty-Two FDA Regulation of Biosimilars - Introduction
-
Chapter Twenty-Three Analog Agency in a Digital World -
Chapter Twenty-Four Twenty-First-Century Technology with Twentieth-Century Baggage -
Chapter Twenty-Five Device-ive Maneuvers -
Chapter Twenty-Six A New Regulatory Function for E-Prescriptions -
Chapter Twenty-Seven Race and the FDA - Contributors
- Index
